ACHILLION PHARMA
at Investor's Business Daily - Tue Aug 19, 5:47PM CDT
ACHILLION PHARMA (ACHN) got a patent OK for ACH-3102, its hepatitis C treatment. Shares rose 2.8% after closing up 3.5%.
Why Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading Today
at The Street - Tue Aug 19, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) rose in after-hours trading Tuesday after the company received a patent for its hepatitis C drug ACH-3102.
Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors
GlobeNewswire - Tue Aug 19, 3:05PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's second generation Phase 2 NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection. This patent is entitled "Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections," and provides a patent term which lasts until 2032.
Can The Uptrend Continue for Achillion (ACHN)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 6:57AM CDT
Can The Uptrend Continue for Achillion (ACHN)?
Achillion Pharmaceuticals
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
Achillion Pharmaceuticals (ACHN) was upgraded to buy from hold by Deutsche Bank, and its price target was raised to 17 from 6 on good news about its new hepatitis drug. Shares rose 3.1% to 9.5.
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.
Should Achillion Pharma (ACHN) Be In Your Portfolio Now? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Aug 18, 2:20PM CDT
ACHN is soaring today, but have investors already missed all the big gains?
Achillion Pharmaceuticals Up On Buyout Rumors
at Investor's Business Daily - Mon Aug 18, 12:52PM CDT
Achillion Pharmaceuticals (ACHN) stock touched an 18-month high for the second straight trading day on Monday, after Deutsche Bank upgraded the biotech startup and boosted price target on positive news about its new hepatitis drug. Achillion stock...
3 Big Stocks on Traders' Radars
at The Street - Mon Aug 18, 11:02AM CDT
Here's how to trade some of the most active stocks on the market today.
Why Achillion Pharmaceuticals (ACHN) Stock Hit a One-Year High Today
at The Street - Mon Aug 18, 9:12AM CDT
Achillion Pharmaceuticals (ACHN) hit a 52-week high of $10.10 on Monday after Deutsche upgraded the stock and increased its price target 183%.
Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 7:44AM CDT
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares gain nearly 10% on the day.
Nasdaq stocks posting largest percentage increases
AP - Fri Aug 15, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod
at Investor's Business Daily - Fri Aug 15, 4:44PM CDT
Big-cap biotech Gilead Sciences (GILD) rose 3.2% to 99.49 on the stock market today, hitting a new all-time high Friday after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.'s...
Why Achillion Pharmaceuticals, Inc. Stock Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Aug 15, 1:50PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Achillion Pharmaceuticals , a...
Why Achillion Pharmaceuticals (ACHN) Stock Surged to a One-Year High Today
at The Street - Fri Aug 15, 9:05AM CDT
Achillion Pharmaceuticals (ACHN) surged to a 52-week high of $9.94 on Friday after the company announced its experimental hepatitis C drug ACH-3102 cured all patients in a mid-stage trial.
Achillion rises on hepatitis C drug study
AP - Fri Aug 15, 8:05AM CDT
NEW YORK (AP) — Achillion Pharmaceuticals climbed in premarket trading Friday after the company reported promising results from a small clinical trial of an experimental hepatitis C drug.
Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
GlobeNewswire - Fri Aug 15, 5:59AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve genotype 1 chronic hepatitis C virus (HCV) infection. Of the 12 patients treated, 100 percent (n=12/12) remained HCV RNA undetectable four weeks after completing therapy (SVR4). Based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir.
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics
PR Newswire - Wed Aug 13, 7:50AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average finished the session at 16,560.54, down 0.06% and the S&P 500 closed at 1,933.75, down 0.16%. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.14% lower at 699.06, and the index has declined 1.94% in the previous one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), XOMA Corp. (NASDAQ: XOMA), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
Achillion Pharmaceuticals Up on Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:10AM CDT
Achillion reported a second quarter 2014 loss of 16 cents per share.